CEO SUMMARY: In Dallas, the relatively short-lived lab company known as Med Fusion has a new owner. After seven years, the lab partnership of Baylor Scott and White, US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories decided to sell their ownership stakes to Quest Diagnostics. The sale comes despite $100 million of capital and
Tag: integrated diagnostics
AT A CONGRESSIONAL BRIEFING LAST WEEK, a federal official charged with regulating laboratory-developed tests made the case that LDTs are inconsistently reliable and thus put patients at risk, according to MedPage Today.
“If you take the same patient sample and you send it to different labs, you can get different results,” stated Jeff Shuren, MD. He is
CEO SUMMARY: In a surprise move that further consolidates national anatomic pathology services, NeoGenomics will acquire Clarient Inc., from General Electric Healthcare. General Electric is getting cash, and preferred and common stock. The two companies announced plans to pursue integrated diagnostic services that would combine lab testing and diagnostic imaging data. The deal is subject
Interesting things are happening in the commercial clinical lab testing market internationally. In New Zealand, district health boards continue a decadeslong trend of squeezing commercial lab companies with the goal of reducing laboratory testing costs and eliminating redundancies. Currently the district health boards (DHBs) of Capital Coast, Hutt Valley, and Wairarapa—representing the the lower part of New Zealand’s north island—are evaluating proposals to consolidate all community and hospital laboratory services into one service entity.
CEO SUMMARY: Working from a consultant’s report and recommendations based on studies dating back to 2006 and 2007, Ireland’s Health Service Executive is moving forward to effect a comprehensive reconfiguration of clinical laboratory testing across the nation. This may be the first time that the government health program of a developed nation has attempted to
CEO SUMMARY: Early this month, the second annual Molecular Summit assembled molecular first movers and early adopters to discuss their efforts to integrate molecular imaging and molecular diagnostics in patient care. One clear message emerged from two days of presentations and discussion: a host of new technologies is ready for clinical introduction and is likely
CEO SUMMARY: Siemens has a vision of tight integration of in vitro and in vivo diagnostics with informatics to support a single goal with two themes: enhancing work flow in healthcare. Theme one is that these technologies can support better productivity of clinical, operational and administrative processes. Theme two is the advancement of “knowledge medicine”
CEO SUMMARY: In the space of just nine weeks, Siemens AG purchased Diagnostic Products Corp. (DPC) and Bayer Diagnostics. Siemens paid $1.86 billion and $5.31 billion, respectively, for the two invitro diagnostics (IVD) companies. Once it closes the acquisition of Bayer Diagnostics, Siemens will have the third largest IVD business in the world. Experts predict
CEO SUMMARY: Despite a decade of consolidation, competition among the world’s largest diagnostics manufacturers remains intense. In response to this competition, Ortho-Clinical Diagnostics (OCD) is preparing a variety of new products and services for its clinical laboratory customers. It’s already exploring diagnostic opportunities in the emerging field of pharmacogenomics. In the field of laboratory management,